GO
Loading...

Novartis AG

More

  • *France's Servier, Israel's Teva among those fined. BRUSSELS, July 9- European Union antitrust regulators fined French drugmaker Servier, Israel's Teva and four others a total of 428 million euros on Wednesday, as they crack down on deals which block cheaper generic medicine.

  • *EU shift to Avastin a threat to Novartis, Bayer profits. PARIS, July 8- French lawmakers voted on Tuesday to allow the use of Roche's cancer drug Avastin as a cheap alternative eye treatment, in a budget-minded move critics fear could put patients' health- and company profits- at risk.

  • TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.

  • FRANKFURT, July 1- German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone- each worth more than $1 billion- Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter& Gamble Co and Novartis.

  • FRANKFURT, July 1- German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone- each worth more than $1 billion- Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter& Gamble Co and Novartis.

  • TOKYO, July 1- Tokyo prosecutors said on Tuesday they will charge the Japanese unit of Novartis AG and a former employee in connection with allegations of data manipulation in promoting its best-selling blood pressure drug Diovan.

  • Business events scheduled for the coming month Friday, 27 Jun 2014 | 2:13 PM ET

    WASHINGTON— Institute for Supply Management releases its manufacturing index for June, 10 a.m.; Commerce Department releases construction spending for May, 10 a.m.. WASHINGTON— Commerce Department releases factory orders for May, 10 a.m..

  • WASHINGTON/ MUMBAI, June 27- India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

  • *Move bolsters Shire in defence against AbbVie. *AbbVie to put its case to Shire shareholders- source. LONDON, June 25- Shire, which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.

  • *European Commission declines to comment. BRUSSELS, June 19- EU antitrust regulators are set to fine French drugmaker Servier, Israel's Teva and several of their peers next month for blocking cheaper generic medicine, two people with knowledge of the matter said on Thursday.

  • June 17- Pfizer Inc and rival Swiss drugmaker Novartis AG on Tuesday said they had asked U.S. regulators to approve their vaccines to prevent meningitis infections in people aged 10 to 25..

  • June 16- A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • *Barclays recommendation upgrade lifts Novartis. PARIS, June 10- European stocks inched up on Tuesday, extending a three-week rally, led by gains in defensive Swiss blue-chips such as pharma group Novartis, boosted by an upbeat broker note.

  • *Gemalto boosted by Chinese contract. PARIS, June 10- European equities climbed to new peaks on Tuesday, with Germany's DAX stock market setting a new record high.

  • Early movers: BRCM, MYL, GOOG, Z & more Monday, 2 Jun 2014 | 7:37 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • What new GSK cancer deal shows about pharma market Monday, 2 Jun 2014 | 3:33 AM ET

    The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.

  • CHICAGO, May 31- Cancer doctors should consider the financial as well as the medical impact of treatment for patients as healthcare costs continue to grow faster than the overall economy, according to experts in Chicago at the annual meeting of the world's largest organization of oncologists.

  • NEW YORK, May 29- A federal judge on Thursday refused to dismiss a U.S. government lawsuit accusing Novartis AG of civil fraud for having conducted two illegal kickback schemes to boost sales of drugs covered by Medicare and Medicaid.